BIO 2025 this year came at a uniquely fraught moment for vaccination in the United States just days after HHS Secretary ...

Liquid biopsies are reshaping colon cancer detection, particularly in addressing the rise in early-onset cases.

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...

That is the conclusion of a study in The Lancet, which has tracked the take-up of childhood vaccinations for diseases like ...

Making good on his promise to move with "historic speed and strength", in his first weeks back in office President Donald ...

The STAAR trial showed that a one-shot dose of ST-920 – now known as isaralgagene civaparvovec – was able to improve kidney ...

Trying to tackle all challenges at once will likely cause even more issues in the future; instead of spreading out, focus on ...

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.

Join us at Axtria Ignite 2025 on 4th to 5th June to explore and lead in the agentic era. Learn from industry experts and leaders shaping the future of business.

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological cancer multiple myeloma, in the latest stage of the medicine's renaissance.

Explore this exclusive interview with Remco op den Kelder as he answers 12 insightful questions that provide a unique glimpse into his life and perspectives.